Addis R C, Bulte J W M, Gearhart J D
Clin Pharmacol Ther. 2008 Mar;83(3):386-9. doi: 10.1038/sj.clpt.6100384.
Human embryonic stem (ES) cells are an attractive tool for cell-based therapies because of their limitless capacity for proliferation and their ability to differentiate into all cell types of the body. However, these features introduce certain unique risks that must be considered in developing transplantation strategies for clinical use. We outline these risks and examine current approaches to address them, both before and after transplantation.
人类胚胎干细胞(ES细胞)因其无限的增殖能力以及分化为机体所有细胞类型的能力,成为基于细胞治疗的一种有吸引力的工具。然而,这些特性带来了某些独特风险,在开发临床应用的移植策略时必须加以考虑。我们概述这些风险,并研究在移植前后应对这些风险的当前方法。